Tremelimumab and durvalumab therapy in lung cancer

Phase III VOLGA: durvalumab + tremelimumab + enfortumab vedotin for neoadjuvant MIBCПодробнее

ASCO 2024 - LBA4: The ADRIATIC StudyПодробнее

ILLUMINATE: Durvalumab, Tremelimumab, and Chemotherapy in EGFR Mutant NSCLC | Dr. Ankur Punia| CRSFПодробнее

Four chemo cycles given with durvalumab ± tremelimumab optimise response in patients with mNSCLCПодробнее

POSEIDON: 4 year follow up of durvalumab and tremelimumab in NSCLCПодробнее

EMERALD-3: tremelimumab + durvalumab with or without lenvatinib combined with TACE in HCCПодробнее

INFINTY: tremelimumab and durvalumab in MSI-high GC/GEJCПодробнее

JCO Article Insights: Phase III POSEIDON Clinical Trial ResultsПодробнее

Restorative microbiota therapy with chemo-immunotherapy in NSCLCПодробнее

MOA of IMFINZI in 1L mNSCLC - Narrated by Debbie IrwinПодробнее

HIMALAYA: tremelimumab + durvalumab in unresectable HCCПодробнее

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLCПодробнее

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCCПодробнее

Durvalumab Plus Tremelimumab With Radiation for Muscle-Invasive Bladder CancerПодробнее

HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC?Подробнее

Webinar: Combination of Durvalumab, Bevacizumab, Tremelimumab & Transarterial ChemoembolizationПодробнее

HIMALAYA: tremelimumab + durvalumab in unresectable HCCПодробнее

Dr. Mounika Boppana - Durvalumab, with or without tremelimumab, plus platinum–etoposide versusПодробнее

ASCO 2021 Lung Recap: Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo AloneПодробнее

Tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanomaПодробнее